z-logo
Premium
Estradiol and Tamoxifen produces acute and chronic neuroprotective effects after spinal cord injury
Author(s) -
Colon Jennifer Marie,
Mosquera Laurivette,
Santiago Jose M,
Torrado Aranza,
Melendez Margarita,
Segarra Annabell C.,
RodriguezOrengo Jose,
Miranda Jorge D.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.691.3
Subject(s) - neuroprotection , spinal cord injury , tamoxifen , medicine , ovariectomized rat , pharmacology , estrogen , estrogen receptor , lesion , reactive oxygen species , antagonist , spinal cord , endocrinology , receptor , chemistry , surgery , cancer , biochemistry , psychiatry , breast cancer
Estradiol (E 2 ) is a multi‐active steroid that may offer neuroprotection via diverse mechanisms of action. Data on the neuroprotective role of E 2 after spinal cord injury (SCI) is still controversial. We hypothesized that continuous E 2 administration will provide beneficial recovery for injured rats at the behavioral, cellular and molecular level. Tamoxifen (TAM) treatment was evaluated in order to reduce possible detrimental effects from E 2 administration. Female ovariectomized Sprague Dawley rats were surgically implanted with E 2 implants or MPP‐dihydrochloride, an Estrogen Receptor α (ER‐α) antagonist, and then injured at the T10 level. Rats treated with E 2 improved locomotor function in three different tests and MPP‐dihydrochloride treatment confirmed that the effects were ER‐α mediated. E 2 treated rats also showed a reduction in reactive oxygen species (ROS), a reduced lesion cavity and an upregulated ER‐α. Rats treated with TAM had a reduced ROS levels and recovered some locomotor activity. Results suggest that E 2 mediates neuroprotection in SCI by improving locomotor function, reducing the extent of the lesion and ROS while TAM administration suggest a safer, alternative treatment for SCI. Sponsored by the MBRS/RISE (R25GM061838), RCMI (G12RR003051 & G12MD007600), NIH/NINDS (NS39405), and MBRS‐SCORE (2S066M8224) programs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom